Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease

BACKGROUND: Ustekinumab was approved in Europe for the treatment of adults with moderate to severe Crohn's disease (CD) in 2016, and there is an urgent need for data on its everyday use. AIM: To obtain data on the daily use of ustekinumab. METHODS: This is a retrospective monocentric study. Pat...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:World J Gastroenterol
Prif Awduron: Hoffmann, Peter, Krisam, Johannes, Wehling, Cyrill, Kloeters-Plachky, Petra, Leopold, Yvonne, Belling, Nina, Gauss, Annika
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Baishideng Publishing Group Inc 2019
Pynciau:
Retrospective Study
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6710179/
https://ncbi.nlm.nih.gov/pubmed/31496626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v25.i31.4481
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg